Tirzepatide prior authorization: criteria, appeal strategy, and the 5-year math
A successful PA converts $1,100/month to a copay — worth ~$8,000 over five years versus flat-rate compounded, ~$64,000 versus retail. Here's the evidence that gets it approved.
Standard prior authorization criteria for tirzepatide
PA criteria vary by plan and are not standardized. The most common elements we see across commercial formularies as of mid-2026: BMI ≥30, or BMI ≥27 with at least one qualifying obesity-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, HFpEF, or cardiovascular disease); documented attempt at lifestyle intervention (usually 90–180 days); prescriber attestation of obesity as a chronic disease; and, for some plans, step therapy requiring a documented trial of another weight-management agent. The indication matters too: Mounjaro (tirzepatide for type 2 diabetes) is covered on more formularies than Zepbound (tirzepatide for weight management).
| PA requirement | How to address it |
|---|---|
| BMI ≥30 (or ≥27 + comorbidity) | Document current BMI; list all qualifying comorbidities even if not the primary indication |
| Prior lifestyle intervention | Dietitian visit notes, medically supervised program records, or primary-care documentation |
| Step therapy (prior weight-loss agent) | Document prior agent, dose, duration, and reason for discontinuation or inadequate response |
| Comorbidity documentation | List ICD-10 codes for all qualifying conditions: hypertension (I10), dyslipidemia (E78.5), HFpEF (I50.3), OSA (G47.33), T2D (E11.9) |
| Medical necessity letter | Request your prescriber write a narrative citing SUMMIT/SURMOUNT outcomes relevant to your conditions |
Using cardiovascular comorbidities as leverage
The SUMMIT trial changed the insurance argument. Before SUMMIT, obesity was often treated by insurers as a lifestyle condition; post-SUMMIT, tirzepatide has level-1 evidence for reducing heart failure events in patients with HFpEF and obesity. If you have HFpEF, hypertension, sleep apnea, or established cardiovascular disease alongside obesity, your prescriber can now cite a phase 3 trial showing a 38% reduction in serious cardiac events to a medical reviewer. This reframing — obesity as a driver of cardiovascular disease, not a cosmetic concern — is the single most powerful lever in a PA appeal for many patients.
Appealing a denial: the process and the evidence
A first denial is not a final answer. ACA-compliant plans must allow internal appeal and, after exhausting that, external review by an independent organization. The appeal letter should include: the specific coverage denial reason, the medical evidence that contradicts it (SUMMIT, SURMOUNT, FDA labeling), the treating physician's clinical rationale, and documentation of how the comorbidity meets medical necessity criteria. Your state insurance commissioner's office and patient advocacy organizations can assist with external appeals.
Brand PA vs cash-pay compounded: the math that makes the PA worth pursuing
A successful brand PA converts tirzepatide from $1,000–$1,350/month to a copay — often $25–$100/month with commercial insurance. At $50/month versus $186/month flat-rate compounded, that's roughly $1,600 saved annually. Over five years of maintenance therapy, a successful PA is worth approximately $8,000 versus flat-rate compounded, and approximately $64,000 versus brand retail out-of-pocket. The PA process is worth a significant time investment.
Frequently asked questions
How do I get prior authorization for Zepbound?
The standard PA requires BMI ≥30 (or ≥27 with a qualifying comorbidity), documented prior lifestyle intervention, and often step therapy. Your prescriber submits the PA; you can strengthen it by providing complete comorbidity documentation and supporting the medical necessity narrative with trial evidence like SUMMIT.
What comorbidities qualify for tirzepatide prior authorization?
Common qualifying comorbidities include type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, heart failure with preserved ejection fraction (HFpEF), and established cardiovascular disease. Post-SUMMIT, HFpEF with obesity carries particularly strong clinical evidence for prior authorization.
What do I do if tirzepatide prior authorization is denied?
File an internal appeal with your insurer with a letter from your prescriber citing specific clinical evidence (SUMMIT for cardiac patients, SURMOUNT for weight management), complete comorbidity documentation, and the specific reason the denial is clinically incorrect. After internal appeal, you can request external review by an independent organization.
Is it worth pursuing brand PA instead of using compounded tirzepatide?
A successful PA converting to a $50/month copay saves roughly $1,600/year versus flat-rate compounded at $186/month, or about $8,000 over five years. Given that the appeal process is free and the evidence base is strong, pursuing PA first is almost always worth the effort for insured patients.
References
- Eli Lilly. Zepbound (tirzepatide) Prescribing Information — indication and coverage information.
- Bhatt DL, et al. SUMMIT trial (HFpEF). N Engl J Med. 2024.
- CMS. ACA internal and external appeal requirements for health plans.
- TirzepatidePriceGuide.com insurance playbook and July 2026 price report.
Clinical data from published trials and FDA labeling; pricing from provider-advertised rates checked July 2026. Not medical or financial advice.